Rapid Assessment of Cardiovascular Risk Among Users of Smoking Cessation Drugs Within the US Food and Drug Administration's Mini-Sentinel Program

    Basic Details
    Date
    Monday, May 13, 2013
    Type
    Publication
    Medical Product
    bupropion
    smoking cessation drug
    varenicline tartrate
    Health Outcome(s)
    acute coronary occlusion without myocardial infarction
    acute myocardial infarction (AMI)
    cardiovascular outcome
    intermediate coronary syndrome
    unstable angina
    Description

    This article describes a Mini-Sentinel modular program-based one-time rapid assessment of the risk of a composite cardiovascular outcome associated with new use of smoking cessation drugs, including varenicline and bupropion. Modular programs are adaptable standardized programs.

    Information
    Time Period
    2006-2011
    Population / Cohort
    All individuals 18 years of age or older
    Data Source(s)
    Mini-Sentinel Distributed Database (MSDD)
    Author(s)

    Sengwee Toh ScD; Meghan A. Baker MD, ScD; Jeffrey S. Brown PhD; Cynthia Kornegay PhD; Richard Platt MD, MS

    Corresponding Author

    S. Toh, Department of Population Medicine, Harvard Pilgrim Health Care Institute and Harvard Medical School, 401 Park Drive, Suite 401 East, Boston, MA 02215, USA. E-mail: darren_toh@harvardpilgrim.org